Ardelyx (NASDAQ: ARDX) net income
Ardelyx reported a net loss of $61.6m for fiscal 2025; in fiscal 2024 it reported a net loss of $39.1m. Earnings per share were −$0.26.
Ardelyx's best year of the last 10 was fiscal 2024. It reported a loss in 10 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$61.6m | — | −15.1% | −$0.26 |
| 2024 | −$39.1m | — | −11.7% | −$0.17 |
| 2023 | −$66.1m | — | −53.1% | −$0.30 |
| 2022 | −$67.2m | — | −128.9% | −$0.42 |
| 2021 | −$158.2m | — | −1,566.5% | −$1.52 |
| 2020 | −$94.3m | — | −1,245.7% | −$1.05 |
| 2019 | −$94.9m | — | −1,797.8% | −$1.47 |
| 2018 | −$91.3m | — | −3,502.0% | — |
| 2017 | −$64.3m | — | −153.2% | — |
| 2016 | −$112.4m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Ardelyx net income compared with its sector
By net income for its latest fiscal year, Ardelyx ranks 279th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Ardelyx, −15.1%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 277th | Fulgent Genetics | −$60.5m | −18.8% |
| 278th | STLN | −$60.6m | −12.1% |
| 279th | Ardelyx | −$61.6m | −15.1% |
| 280th | Alto Neuroscience | −$63.2m | — |
| 281st | Lineage Cell Therapeutics | −$63.5m | −436.5% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Ardelyx
- How much did Ardelyx earn in fiscal 2025?
- Ardelyx reported a net loss of $61.6m for fiscal 2025. In fiscal 2024 it reported a net loss of $39.1m.
- What are the earnings per share of Ardelyx?
- They were −$0.26 in fiscal 2025, compared with −$0.17 in fiscal 2024.
- Where does Ardelyx rank in its sector by net income?
- It ranks 279th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Ardelyx come from?
- From the annual report (Form 10-K) that Ardelyx files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Ardelyx files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Ardelyx: the Ardelyx page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.